Kriya Therapeutics, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-08-15.
Kriya Therapeutics, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on August 15, 2025. The filing reports $320.82M sold. Its industry group is Biotechnology. It names Shankar Ramaswamy (Executive Officer, Director), Trit Garg (Director), Ryan Gallagher (Director) (SEC Form D/A, August 15, 2025).
In its own words: “Kriya is building durable medicines designed to replace chronic re-treatment with a single administration—therapeutic medicines that can scale to millions.” (kriyatx.com, checked October 31, 2026)
Is this your company?
Sell to companies like Kriya Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-15 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Kriya Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Kriya Therapeutics, Inc., from the filings we hold.
Biotechnology raises by companies based in North Carolina, filed within 90 days of this one, largest first.
Get an email when Kriya Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Kriya Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Kriya Therapeutics, Inc. →Get the full cited report on Kriya Therapeutics, Inc.
What the filing shows about Kriya Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kriya Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Kriya Therapeutics, Inc.'s address as 4105 Hopson Road, Morrisville, NC 27560.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Kriya Therapeutics, Inc. →
Amended on 2025-09-10: the offering size changed from $313,297,440 to $320,822,412; the amount sold changed from $313,297,440 to $320,822,412; the number of investors changed from 2 to 10. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Kriya Therapeutics, Inc. See pricing
Kriya Therapeutics, Inc. is a registered filer with the SEC (CIK 1811209) and has filed since 2023-07-27. 3 filings are on record, the latest on 2025-09-10.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Kriya Therapeutics, Inc.'s Form D of 2025-08-15 names Shankar Ramaswamy, Trit Garg, Ryan Gallagher and 12 more as its officers, directors or promoters.
Its new offerings report $313.30M sold across 1 offering, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
Shankar Ramaswamy is named as Executive Officer and Director on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Trit Garg is named as Director on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Ryan Gallagher is named as Director on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Roger Jeffs is named as Director on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Keith Manchester is named as Director on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
James Momtazee is named as Director on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Ilan Oren is named as Director on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Akshay Rai is named as Director on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Saira Ramasastry is named as Director on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Neelaksh Varshney is named as Director on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Curt Herberts is named as Executive Officer on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Katherine Eade is named as Executive Officer on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Brian Furmanski is named as Executive Officer on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Britt Petty is named as Executive Officer on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
Michele Stone is named as Executive Officer on the Form D that Kriya Therapeutics, Inc. filed with the SEC on 15 August 2025, one of 15 people that filing names.
15 people named on the filing — 6 holding an executive role and 9 as directors only.
Named as of the 2025-08-15 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
Of the 15 names on this filing, 12 are drawn here to keep the picture readable. The People tab lists them all.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Kriya Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Kriya Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kriya Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Kriya Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Kriya Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Kriya Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Raleigh-Durham
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/kriya-therapeutics-inc-form-d-25000001